Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
BioDrugs · 2024
DOI: 10.1007/s40259-024-00654-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDrugs, 2024. Verfasst von Zhenjie Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine, CUHK-GIBH CAS Joint Research Laboratory on Stem Cell and Regenerative Medicine, The Chinese Unive…. Hauptthemen laut MEDLINE: Hemophilia A, CRISPR-Cas Systems, Gene Editing, Drug Development. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University Grants Committee, Innovation and Technology Commission - Hong Kong, Chinese University of Hong Kong.
Abstract (Originalsprache)
The remarkable advance in gene editing technology presents unparalleled opportunities for transforming medicine and finding cures for hereditary diseases. Human trials of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9)-based therapeutics have demonstrated promising results in disrupting or deleting target sequences to treat specific diseases. However, the potential of targeted gene insertion approaches, which offer distinct advantages over disruption/deletion methods, remains largely unexplored in human trials due to intricate technical obstacles and safety concerns. This paper reviews the recent advances in preclinical studies demonstrating in vivo targeted gene insertion for therapeutic benefits, targeting somatic solid tissues through systemic delivery. With a specific emphasis on hemophilia as a prominent disease model, we highlight advancements in insertion strategies, including considerations of DNA repair pathways, targeting site selection, and donor design. Furthermore, we discuss the complex challenges and recent breakthroughs that offer valuable insights for progressing towards clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Biomedical Sciences, Faculty of Medicine, CUHK-GIBH CAS Joint Research Laboratory on Stem Cell and Regenerative Medicine, The Chinese University of Hong Kong, Room 105A, Lo Kwee-Seong Integrated Biomedical Sci…
- Centre for Regenerative Medicine and Health, Hong Kong Institute of Science and Innovation, Chinese Academy of Sciences, Hong Kong SAR, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai,…
- Centre for Regenerative Medicine and Health, Hong Kong Institute of Science and Innovation, Chinese Academy of Sciences, Hong Kong SAR, China. fengbo@cuhk.edu.hk.
- Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China. fengbo@cuhk.edu.hk.
Förderung
- University Grants Committee
- Innovation and Technology Commission - Hong Kong
- Chinese University of Hong Kong
Zitieren
APA
Zhang, Z., Zhang, S., Wong, H. T., Li, D., & Feng, B. (2024). Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight. BioDrugs. https://doi.org/10.1007/s40259-024-00654-5
Vancouver
Zhang Z, Zhang S, Wong HT, Li D, Feng B. Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight. BioDrugs. 2024. doi:10.1007/s40259-024-00654-5
BibTeX
@article{Zhang2024,
author = {Zhang, Zhenjie and Zhang, Siqi and Wong, Hoi Ting and Li, Dali and Feng, Bo},
title = {Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight},
journal = {BioDrugs},
year = {2024},
doi = {10.1007/s40259-024-00654-5}
}
EUVIMED